Edema News and Research

RSS

Edema means swelling caused by fluid in your body's tissues. It usually occurs in the feet, ankles and legs, but it can involve your entire body.

Implicit licenses clinical stage antibody program from Lilly

Implicit Bioscience Ltd has announced the acquisition of the clinical-stage monoclonal antibody IC14 from Eli Lilly and Company. Implicit has paid an undisclosed consideration combining cash and stock to Lilly. Lilly will also receive a royalty on future IC14 sales.

25 Feb 2009

New technology could save vision of millions

In the blink of an eye, people at risk of becoming blind can now be screened for eye diseases such as diabetic retinopathy and age-related macular degeneration.

18 Feb 2009

FDA grants priority review of Cinryze C1 inhibitor as treatment for acute attacks of hereditary angioedema

ViroPharma Incorporated has announced that the U.S. Food and Drug Administration (FDA) has granted priority review for Cinryze C1 Inhibitor (human) as a treatment for acute attacks of Hereditary Angioedema (HAE).

5 Feb 2009

Protease inhibitor found to aid diabetic retinopathy treatment

Researchers from Joslin Diabetes Center, Boston, and ActiveSite Pharmaceuticals, Inc., San Francisco, announced today that they have demonstrated that a specific inhibitor of the protease plasma kallikrein, ASP-440, developed by ActiveSite Pharmaceuticals, may provide a new therapeutic approach for treatment of diabetic retinopathy, the most common eye-related complication of diabetes.

21 Jan 2009

Zometa (zoledronic acid) shown to enhance chemotherapy in reducing breast tumor size

New data released demonstrates that the addition of Zometa (zoledronic acid) injection to standard chemotherapy before breast cancer surgery reduces the size of breast tumors more effectively than chemotherapy alone in women with early-stage disease.

14 Dec 2008

Promacta (eltrombopag) shown to increase platelet counts and reduce bleeding in chronic immune thrombocytopenic

GlaxoSmithKline has announced positive safety and efficacy results from RAISE (RAndomized placebo- controlled ITP Study with Eltrombopag), a Phase III study of Promacta (eltrombopag) in adults with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who had received one or more prior ITP therapies.

7 Dec 2008

ViroPharma Inc. submits sBLA for Cinryze to treat acute attacks of hereditary angioedema

ViroPharma Inc. has announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Cinryze C1 Inhibitor (human) as a treatment for acute attacks of hereditary angioedema (HAE).

1 Dec 2008

Scientists present 'moving' theory behind bacterial decision-making

Biochemists at North Carolina State University have answered a fundamental question of how important bacterial proteins make life-and-death decisions that allow them to function, a finding that could provide a new target for drugs to disrupt bacterial decision-making processes and related diseases.

24 Nov 2008

High levels of social support may protect brain during stroke

New research in mice suggests that high levels of social support may provide some protection against strokes by reducing the amount of damaging inflammation in the brain.

18 Nov 2008

Ellex Medical Lasers announces results of retina regeneration therapy

Ellex Medical Lasers has announced the six-month clinical study results for the groundbreaking treatment Retina Regeneration Therapy (Ellex 2RT) at the annual meeting of the American Academy of Ophthalmology.

10 Nov 2008

Pycnogenol cuts jetlag in half

Scientists have found that Pycnogenol, a natural plant extract from the bark of pine trees, can reduce jetlag symptoms by half. Pycnogenol is the patented trade name for a water extract of the bark of the French maritime pine (Pinus pinaster ssp. atlantica), which is grown in coastal southwest France.

9 Nov 2008

Pine bark extract reduces jetlag

A new study published in the journal of Minerva Cardioangiologica reveals Pycnogenol, pine bark extract from the French maritime pine tree, reduces jetlag in passengers by nearly 50 percent.

6 Nov 2008

Scientists map molecular regulation of fat-cell genetics

A research team led by Mitchell Lazar, MD, PhD, Director of the Institute for Diabetes, Obesity, and Metabolism at the University of Pennsylvania School of Medicine, has used state-of-the-art genetic technology to map thousands of positions where a molecular "master regulator" of fat-cell biology is nestled in DNA to control genes in these cells.

5 Nov 2008

Scientists map molecular "master regulator" of fat-cell biology

5 Nov 2008

Anti-VEGF drugs for retinal diseases could have serious side effects

Scientists at Schepens Eye Research Institute have found that reducing the levels of vascular endothelial growth factor (VEGF), which is best known as a stimulator of new blood vessel growth, in adult mice causes the death of photoreceptors and Muller glia -- cells of the retina that are essential to visual function.

3 Nov 2008

GlaxoSmithKline believes there is no liver safety issue with Avandia (rosiglitazone maleate)

GlaxoSmithKline today issued the following response to a petition filed by Public Citizen to the U.S. Food and Drug Administration (FDA) on Avandia (rosiglitazone maleate), a highly effective therapy for treating type 2 diabetes when used in the appropriate patient population.

31 Oct 2008

Bisphosphonates for osteoporosis increase risk for heart problems

People who take bisphosphonates for osteoporosis may be at risk for serious atrial fibrillation (AF), or irregular heartbeats, according to a new study.

27 Oct 2008

Data Safety Monitoring Board supports continuation of trial of Iluvien for diabetic macular edema

pSivida Corp. has announced that after completing its review of safety and efficacy data currently available, an independent Data Safety Monitoring Board (DSMB) has once again recommended that the two pivotal Phase III clinical trials, known collectively as the FAME (Fluocinolone Acetonide in Diabetic Macular Edema) Study continue under the current protocol, without change.

25 Sep 2008

Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery

Novartis has announced that Gleevec (imatinib mesylate) tablets, (known as Glivec (imatinib) outside the US, Canada and Israel), has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST).

27 Aug 2008

Maternal deaths following cesarean delivery can be reduced

Maternal death rates have remained constant in the United States for many decades. Are there any improvements in health care that could reduce these rates further?

4 Aug 2008